|
Apr 30
|
Axonics Reports First Quarter 2024 Financial Results
|
|
Apr 24
|
Boston Scientific Announces Results for First Quarter 2024
|
|
Mar 29
|
All You Need to Know About Axonics (AXNX) Rating Upgrade to Buy
|
|
Mar 22
|
Axonics Stockholders Approve Merger Agreement with Boston Scientific
|
|
Mar 21
|
Axonics Provides Update on Inter Partes Review Proceedings
|
|
Mar 14
|
Axonics Receives CE Mark Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System
|
|
Jan 9
|
Why Axonics Stock Soared Today
|
|
Jan 8
|
Boston Scientific to Acquire Axonics For About $3.7 Billion
|
|
Jan 8
|
Axonics Announces Definitive Agreement to be Acquired by Boston Scientific
|
|
Jan 8
|
Boston Scientific Announces Agreement to Acquire Axonics, Inc.
|
|
Jan 8
|
Axonics Reports Preliminary 4Q23 and Fiscal Year 2023 Revenue
|
|
Dec 27
|
Axonics to Present at the J.P. Morgan Healthcare Conference
|
|
Dec 4
|
When Will Axonics, Inc. (NASDAQ:AXNX) Become Profitable?
|
|
Sep 11
|
Axonics (AXNX): A Significantly Undervalued Gem in the Medical Technology Sector?
|
|
Apr 25
|
Axonics to Participate in Upcoming Investor Conferences
|
|
Apr 24
|
Axonics Acquires Technology to Facilitate Easier and Faster Placement of Implantable Leads for Sacral Neuromodulation
|